NYSE - Delayed Quote • USD
Compare
At close: August 30 at 4:00 PM EDT
After hours: August 30 at 7:56 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Joaquin Duato | CEO & Chairman | 6.21M | 14.99M | 1963 |
Mr. Joseph J. Wolk CPA | Executive VP & CFO | 3.17M | -- | 1967 |
Dr. Peter M. Fasolo Ph.D. | Executive VP & Chief Human Resources Officer | 2.15M | -- | 1963 |
Ms. Jennifer L. Taubert | Executive VP & Worldwide Chairman of Innovative Medicine | 3.1M | -- | 1964 |
Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine, R&D | 8.57M | -- | 1958 |
Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | -- | -- | 1972 |
Mr. James Swanson | Executive VP & Chief Information Officer | -- | -- | 1966 |
Ms. Jessica Moore | Vice President of Investor Relations | -- | -- | -- |
Mr. Dirk Brinckman | Chief Compliance Officer | -- | -- | -- |
Ms. Elizabeth Forminard | Executive VP & Chief Legal Officer | -- | -- | 1971 |
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States
732 524 0400 https://www.jnj.com
- Sector:
- Healthcare
- Industry:
- Full Time Employees:
- 131,900
Drug Manufacturers - General
Description
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Corporate Governance
Johnson & Johnson’s ISS Governance QualityScore as of August 28, 2024 is 2. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 2; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
September 10, 2024 at 12:00 AM UTC
Dividend Date
October 15, 2024 at 12:30 PM UTC
Johnson & Johnson Earnings Date
Recent Events
August 29, 2024 at 12:00 AM UTC
N-PX: Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
See Full Filing
August 27, 2024 at 12:00 AM UTC
Ex-Dividend Date
August 26, 2024 at 12:00 AM UTC
8-K: Corporate Changes & Voting Matters
See Full Filing
July 30, 2024 at 12:00 AM UTC
SC 13G: Tender Offer/Acquisition Reports
See Full Filing
July 25, 2024 at 12:00 AM UTC
10-Q: Periodic Financial Reports
See Full Filing
July 17, 2024 at 12:00 AM UTC
8-K: Corporate Changes & Voting Matters
See Full Filing
June 25, 2024 at 12:00 AM UTC
11-K/A: Annual report of employee stock purchase
See Full Filing
June 24, 2024 at 12:00 AM UTC
11-K: Annual report of employee stock purchase
See Full Filing
Related Tickers
MRK Merck & Co., Inc.
118.45
+0.84%
PFE Pfizer Inc.
29.01
+1.01%
ABBV AbbVie Inc.
196.31
+0.58%
BMY Bristol-Myers Squibb Company
49.95
+0.46%
LLY Eli Lilly and Company
960.02
+2.11%
AMGN Amgen Inc.
333.83
+0.85%
GILD Gilead Sciences, Inc.
79.00
-0.57%
GSK GSK plc
43.91
+0.39%
AZN AstraZeneca PLC
87.62
+0.37%
NVS Novartis AG
120.89
+0.39%